Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Company Overview - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a commercial stage pharmaceutical company that markets and sells four different types of drugs for the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle loss [2]. Investment Insights - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch, buy and sell ratings, product sales forecasts, and integrated financial statements [2]. Analyst Background - Edmund Ingham, a biotech consultant with over five years of experience in the sector, has compiled detailed reports on more than 1,000 companies and leads the Haggerston BioHealth investing group [2].